	US 12,285,486 B2
	Pharmaceutical composition in solid extruded form
Jiannan Lu, East Hanover, NJ (US); and Sakae Obara, Tokyo (JP)
Assigned to SE Tylose USA, Inc; and Shin-Etsu Chemical Co., Ltd., Tokyo (JP)
Filed by SE Tylose USA, Inc., Plaquemine, LA (US); and Shin-Etsu Chemical Co., Ltd., Tokyo (JP)
Filed on Dec. 28, 2020, as Appl. No. 17/134,668.
Application 17/134,668 is a continuation of application No. 16/046,488, filed on Jul. 26, 2018, abandoned.
Claims priority of provisional application 62/541,928, filed on Aug. 7, 2017.
Prior Publication US 2021/0113700 A1, Apr. 22, 2021
Int. Cl. A61K 9/16 (2006.01); A61K 31/4418 (2006.01); A61K 31/496 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01)

CPC A61K 47/38 (2013.01) [A61K 31/4418 (2013.01); A61K 31/496 (2013.01); A61K 47/26 (2013.01)]

17 Claims

1. An extrusion process for forming a tablet, a pellet or granule, the process comprising:

forming an extrudable composition by forming a pharmaceutical composition consisting essentially of one or more pharmaceuticals or nutraceuticals, hydroxypropylmethyl cellulose acetate succinate, and 20 to 50 percent of isomalt

extruding the extrudable composition at a temperature of 100° to 200° C. to form an extrudate and;

compressing the extrudate into a tablet, a pellet or granule to provide a tablet, a pellet or a granule having improved tensile strength and hardness as compared to the pharmaceutical composition comprising hydroxypropylmethyl cellulose acetate succinate without 20 to 50 percent isomalt.